CELLINK BIO X6
The 6 printhead 3D bioprinter that epitomizes user-friendly flexibility and optimizing high-throughput 3D cell culturing to create the future of medicine.
When CELLINK released the first universal bioink in 2016 and subsequently launched the world’s first affordable 3D bioprinter, it democratized the cost of entry for researchers around the world and played a major role in turning the then up-and-coming field of 3D bioprinting into a thriving $1 billion industry. Today, the company’s best-in-class bioinks, bioprinters, software and services have been cited in over 1000 publications and are trusted by more than 1,600 academic, pharmaceutical and industrial labs. With a comprehensive portfolio of world-class 3D bioprinters and bioinks CELLINK’s technology enables the printing of human tissues and organs, which enable faster and more accurate models for drug development, while replacing animal experiments and paving the way to save lives by reducing organ rejection and potentially solve the problem with lack of donors. 2022 CELLINK made a strategic investment to reach our business mission and continue to push the boundaries of how 3D bioprinting can contribute to the future of health. Visit www.cellink.com to learn more.
The 6 printhead 3D bioprinter that epitomizes user-friendly flexibility and optimizing high-throughput 3D cell culturing to create the future of medicine.
The CELLINK BIO X 3D Bioprinter is the most userfriendly yet high quality, cost-effective bioprinting platform in the world. The system provides our patented Clean Chamber Technology, exchangable heat...
When CELLINK released the first universal bioink in 2016 and subsequently launched the world’s first affordable 3D bioprinter, it democratized the cost of entry for researchers around the world and played a major role in turning the then up-and-coming field of 3D bioprinting into a thriving $1 billion industry. Today, the company’s best-in-class bioinks, bioprinters, software and services have been cited in over 1000 publications and are trusted by more than 1,600 academic, pharmaceutical and industrial labs. With a comprehensive portfolio of world-class 3D bioprinters and bioinks CELLINK’s technology enables the printing of human tissues and organs, which enable faster and more accurate models for drug development, while replacing animal experiments and paving the way to save lives by reducing organ rejection and potentially solve the problem with lack of donors. 2022 CELLINK made a strategic investment to reach our business mission and continue to push the boundaries of how 3D bioprinting can contribute to the future of health. Visit www.cellink.com to learn more.
100 Franklin St, Boston, MA 02110, USA Arvid Wallgrens Backe 20, 41346 Gothenburg Sweden
Website link